
Sign up to save your podcasts
Or
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by guests Thomas Tadros, MD, and Ashraf Sabe, MD, of Brigham and Women's Hospital, to discuss efficacy and safety of hybrid epicardial and endocardial ablation versus endocardial ablation in patients with persistent and longstanding persistent atrial fibrillation. In this randomized trial, hybrid surgical and catheter ablation was more effective than catheter ablation alone in persistent atrial fibrillation without significant procedural risk increase.
https://www.hrsonline.org/education/TheLead
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00229-8/fulltext
Host Disclosure(s):
W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic
Contributor Disclosure(s):
T. Tadros: No relevant financial relationships with ineligible companies to disclose.
A. Sabe: No relevant financial relationships with ineligible companies to disclose.
5
77 ratings
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by guests Thomas Tadros, MD, and Ashraf Sabe, MD, of Brigham and Women's Hospital, to discuss efficacy and safety of hybrid epicardial and endocardial ablation versus endocardial ablation in patients with persistent and longstanding persistent atrial fibrillation. In this randomized trial, hybrid surgical and catheter ablation was more effective than catheter ablation alone in persistent atrial fibrillation without significant procedural risk increase.
https://www.hrsonline.org/education/TheLead
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00229-8/fulltext
Host Disclosure(s):
W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic
Contributor Disclosure(s):
T. Tadros: No relevant financial relationships with ineligible companies to disclose.
A. Sabe: No relevant financial relationships with ineligible companies to disclose.
322 Listeners
170 Listeners
872 Listeners
502 Listeners
86,745 Listeners
2,427 Listeners
3,333 Listeners
135 Listeners
195 Listeners
518 Listeners
350 Listeners
424 Listeners
2 Listeners
4 Listeners
52 Listeners